INTRODUCTION
The development of neutralizing anti-factor VIII (FVIII) antibodies is the major complication in the treatment of hemophilia A patients with FVIII products. 1, 2 Longterm application of high doses of FVIII has evolved as an effective therapy to eradicate the antibodies and induce long-lasting immune tolerance. [3] [4] [5] [6] receptors, MHC-class II and co-stimulatory molecules. 9 It is, therefore, reasonable to believe that memory B cells have to be eradicated or functionally inactivated during a successful immune tolerance induction therapy in hemophilia A patients with FVIII inhibitors.
We used a murine model of hemophilia A that is characterized by complete deficiency of functionally active FVIII because of a targeted disruption of exon 17 of the FVIII gene. 10, 11 Intravenous injection of human FVIII into these mice results in high titers of anti-FVIII antibodies that have similar characteristics to those of FVIII inhibitors in patients. [12] [13] [14] [15] Using this model, we demonstrated previously that the only.
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From 4 differentiation of FVIII-specific memory B cells into ASCs depends on the presence of activated T cells and requires CD40-CD40 ligand and CD80/CD86-CD28 costimulatory interactions. 16 Here we show that concentrations of FVIII below the physiological plasma concentration of 0.1 µg/mL (1 U/mL) re-stimulate FVIII-specific memory B cells and induce their differentiation into ASCs. Concentrations above 0.1 µg/mL (1 U/mL), however, inhibit memory-B-cell re-stimulation and prevent the formation of ASCs. This inhibition is irreversible and involves the activation of caspases.
METHODS

Hemophilic E-17 mice
Our colony of fully inbred hemophilic E-17 mice (characterized by a targeted disruption of exon 17 of the FVIII gene) was established with a breeding pair from the original colony 10, 11 and crossed into the C57BL/6J background as described. 17 All mice were male and aged 8-10 weeks at the beginning of the experiments. All studies were carried out in accordance with Austrian federal law (Act BG 501/1989) regulating animal experimentation.
Immunization of mice with FVIII or ovalbumin
Immunization with FVIII: At weekly intervals mice received four intravenous doses of For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From anti-FVIII antibody responses in hemophilic E-17 mice. The recombinant human FVIII used throughout the studies was albumin-free bulk material obtained from Baxter BioScience (Thousand Oaks, California). The recombinant B-domainless murine FVIII was produced in a cell line derived from baby hamster kidney (BHK) and purified as described . 18 Immunization with ovalbumin: Mice were immunized with three intraperitoneal doses of ovalbumin (OVA, Sigma-Aldrich). The OVA contained traces of endotoxin (26 ng endotoxin per mg protein) as detected with the Limulus Amoebocyte Lysat Test (Baxter BioScience, Orth, Austria). The first dose of OVA was 20 µg and the second and third doses were both 10 µg. The interval between the first and second injection was 2 weeks and between the second and third injection 1 week. The OVA was diluted in 100 µL DPBS. This treatment regimen was sufficiently found to develop OVA-specific immunological memory after treatment without adjuvant.
16
Spleen cell preparation
Spleens were obtained 7 days after the last dose of FVIII or OVA. Spleen cells were prepared as described. 16 Where indicated, spleen cells were depleted of T cells by incubation with Mouse pan T (anti-murine Thy 1.2) Dynabeads (Dynal ASA, Oslo, Norway) for 20 minutes at 4°C and subsequent separation with a magnetic device. Tcell depletion as determined by flow cytometry was greater than 99%.
Splenic T cells were isolated from either spleen cells or cells obtained from in vitro cultures by negative selection using a MACS T-cell isolation kit (Milteny Biotec, Auburn, California). The purity of different cell populations was analyzed by flowcytometry as described . 16 only.
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Re-stimulation of memory B cells in vitro
The re-stimulation of memory B cells in vitro was achieved as described. 16 100 U/mL penicillin, 100 mg/mL streptomycin (all from Life Technologies) and 5x10 -5 M ß-mercaptoethanol (Sigma-Aldrich) at 37°C for 3 or 6 days. Different concentrations of FVIII or OVA were added to the cells on day 0 as indicated. After 3 or 6 days of culture, newly formed ASCs were detected by ELISPOT assays as described. 16, 20 To test for the effect of high concentrations of FVIII on T-cell function, CD138 -spleen cells were cultured for 3 days as indicated, washed twice with culture medium and subsequently used for the isolation of T cells by negative selection as described above. T cells were then mixed in a ratio of 1:2 with freshly isolated CD138 -spleen cells depleted of T cells, which were obtained from the spleens of hemophilic mice treated with four doses of FVIII. 
Analysis of FVIII-specific T cells by intracellular cytokine staining
Analysis of FVIII-specific T cells by intracellular cytokine staining was as described. 
RESULTS
High concentrations of FVIII inhibit the re-stimulation of FVIII-specific memory B cells in vitro and in vivo
We reported previously that the differentiation of FVIII-specific memory B cells into ASCs can be stimulated in vitro. 16 Here we show that low concentrations of FVIII We next investigated whether the inhibition of memory B-cell re-stimulation by high concentrations of FVIII could be observed in vivo. We transferred CD138 -spleen cells (containing FVIII-specific memory cells), obtained from hemophilic mice treated with either human or murine FVIII, into naïve mice as described. 16 The resulting mice Mice that had memory cells specific for murine FVIII were treated with a single intravenous dose of either 0.2, 2, 20 or 40 µg of murine FVIII (40 µg was the highest dose that could be applied with the preparation of murine FVIII that was available).
We For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From for boosting the FVIII-specific memory-B-cell response versus inhibiting this response.
Inhibition of memory B-cell re-stimulation is not caused by inhibition of T-cell activation and is not mediated by T cells
Previously, we showed that the re-stimulation of FVIII-specific memory B cells obtained from hemophilic mice immunized with FVIII was dependent on the presence of activated T cells. 16 Therefore, we were interested to know whether the inhibition of The major T-cell cytokines found in culture supernatants after stimulation of spleen cells with FVIII were IL-10 and IFN-γ (Figures 3a, 3b, 3c) , which is consistent with findings we reported previously. 16, 22 To further support these results, we analyzed the frequency of FVIII-specific T cells by intracellular cytokine staining 3 days after restimulation of spleen cells as described. 22 We compared concentrations of 0.01 and 20 µg/mL FVIII, which stimulate and inhibit memory B-cell differentiation, respectively and observed a correlation between the frequency of FVIII-specific T cells producing IL-2, IL-10 or IFN-γ and the concentration of FVIII used for the re-stimulation (data not shown). We did not observe any inhibitory effects of high concentrations of FVIII on T-cell stimulation at the concentrations tested.
We next ask the question whether T cells stimulated by high concentrations of FVIII would still be able to support the re-stimulation and differentiation of FVIII-specific memory B cells. For this purpose, we stimulated CD138 -spleen cells with 20 µg/mL FVIII for 3 or 6 days. After this time, we isolated T cells from the cultures and mixed them with freshly isolated CD138 -spleen cells that were depleted of T cells. We restimulated this cell mixture with 0.01 µg/mL FVIII, the concentration of FVIII found to be optimal for memory B-cell re-stimulation in vitro. We found that T cells that were initially stimulated with 20 µg/mL FVIII were still able to support the re-stimulation and differentiation of FVIII-specific memory B cells (Figure 4a ). These results indicate that high concentrations of FVIII do not induce T cells that suppress the re-stimulation of memory B cells. In subsequent experiments, we investigated whether FVIII would inhibit the re-stimulation of FVIII-specific memory B cells in a system where FVIIIspecific T cells were absent. We showed previously that activated FVIII-specific T only.
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Inhibition of memory B-cell re-stimulation is irreversible and involves the activation of caspases
We next wanted to know whether the inhibitory effect of FVIII on the re-stimulation of FVIII-specific memory B cells is reversible. We re-stimulated FVIII-specific memory cells with either 0.01 µg/mL (stimulatory concentration) or 20 µg/mL FVIII (inhibitory concentration). After 3 days of culture, we washed cells, re-suspended them in culture medium and split them into two aliquots. We stimulated one aliquot with 0.01 µg/mL FVIII and the other aliquot with 20 µg/mL FVIII. Cells that we initially stimulated with 0.01 µg/mL FVIII could be re-stimulated after transfer to 0.01 µg/mL FVIII. However, cells that we initially stimulated with 20 µg/mL FVIII could not be restimulated when we transferred them to 0.01 µg/mL FVIII ( Figure 5 ). These results indicate that the inhibition of memory B-cell re-stimulation by high concentrations of only.
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All experiments (n=3) gave similar results. 
CD138
-spleen cells were obtained from hemophilic mice immunized with human FVIII and re-stimulated with either 0.01 or 20 µg/mL as indicated. Newly formed
ASCs were analyzed after 6 days of culture by ELISPOT assays.
In (a) some of the cultures were pre-incubated with a broad spectrum caspase inhibitor (Z-VAD-FMK) for 4 hours before FVIII was added. As a positive control for apoptosis, part of the cultures was incubated with 0.01 µg/mL FVIII in the presence of an agonistic anti-murine Fas antibody (Jo2). In (b) some of the cultures were incubated in the presence of Fas-Fc. As a negative control for Fas-Fc, part of the cultures was incubated in the presence of a human monoclonal IgG1.
Presented is a typical experiment. Spleens of 5 mice were pooled for cell preparation.
